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ABSTRACT
Objective To investigate the frequency and risk factors
for incident and redetected Chlamydia trachomatis
infection in sexually active, young, multi-ethnic women
in the community.
Design Cohort study.
Setting 20 London universities and Further Education
colleges.
Participants 954 sexually experienced women, mean
age 21.5 years (range 16–27), 26% from ethnic
minorities, who were recruited to the Prevention of
Pelvic Infection (POPI) chlamydia screening trial between
2004 and 2006, and returned repeat postal self-taken
vaginal swabs 11–32 (median 16) months after
recruitment.
Results The estimated annual incidence of chlamydia
infection among 907 women who tested negative at
baseline was 3.4 per 100 person-years (95% CI 2.5 to
4.6 per 100 person-years), but 6.6 per 100 person-years
(95% CI 4.5 to 9.3 per 100 person-years) in the 326
teenagers (<20 years). Predictors of incident chlamydia
infection were age <20 years (relative risk (RR) 4.0,
95% CI 2.1 to 7.5), and (after adjusting for age) a new
sexual partner during 12 months follow-up (RR 4.4,
95% CI 2.0 to 9.9), smoking (RR 2.2 95% CI 1.2 to
3.9), concurrent bacterial vaginosis (RR 2.0 95% CI 1.1
to 3.9) and high risk carcinogenic human papillomavirus
(RR 2.2, 95% CI 1.1 to 4.3). Of 47 women positive for
chlamydia at baseline, 12 (25.5%, 95% CI 13.9% to
40.3%) had redetected infection at a median of
16 months follow-up. Taking into account follow-up time
(65 person-years), the annual redetection rate was
18.5 per 100 person-years (95% CI 9.9 to 30.0
per 100 person-years).
Conclusions One in four women with chlamydia
infection at baseline retested positive, supporting recent
recommendations to routinely retest chlamydia positives.
INTRODUCTION
With the English National Chlamydia Screening
Programme (NCSP) completing its 10th year in
2013, much focus has been on the effectiveness of
this and similar programmes in the USA and
Europe for reaching their aims of controlling chla-
mydia infection through opportunistic screening.
English NCSP guidelines recommend retesting
annually or with every new partner for all
16–24 year olds and, in 2013, began to include
recommending retesting for those found to be posi-
tive.1 In 2012, at 25.8% coverage of 15–24 year
olds, 1 782 122 tests were undertaken in England
with a positivity rate of 7.7%.2 However, recent
UK data from the National Survey of Attitudes and
Lifestyles show little change in the population
prevalence of chlamydia in women in this age
group: 3.2% in 2010 versus 3.1% in 2000.3
It is difﬁcult to measure the incidence and
reinfection rates of Chlamydia trachomatis in
women as it is usually asymptomatic and relies on
affected persons seeking a test. Consequently, there
are few British published data on the incidence and
reinfection rates of chlamydia4–6 and none in
women recruited outside healthcare facilities. We
examined frequency and risk factors for incident
and redetected chlamydia infection in women who
provided follow-up samples in the Prevention of
Pelvic Infection (POPI) chlamydia screening trial.7 8
METHODS
Participants and setting
The design, recruitment methods and participants
of the POPI trial have been described elsewhere.7–10
Brieﬂy, between 2004 and 2006, 2529 sexually
active female students were recruited from London
universities and Further Education colleges to a
chlamydia screening trial. Participants were eligible
if they were aged ≤27 years, sexually active, not
pregnant and had not been tested for chlamydia in
the previous 3 months. At baseline, they completed
a questionnaire on socio-demographic character-
istics and sexual behaviour and provided two self-
taken vaginal specimens. One was used for the
chlamydia screening trial. The other was rolled
over a glass slide for analysis for bacterial vaginosis,
placed in Aptima transport medium and stored at
-80°C for later testing for Mycoplasma genitalium
(by an inhibitor controlled PCR detecting the 16S
ribosomal gene)9 and human papillomavirus (by
Digene Hybrid Capture 2 assay and the Roche
Linear Array Genotyping assay).10 Of 2529 partici-
pants, 94% (2377) were followed up after
12 months by questionnaire and/or medical records
search, and 38% (954) also returned a repeat postal
sample 11–32 (median 16) months after recruit-
ment. As with baseline samples these were tested
for C. trachomatis using TMA (Gen-Probe Inc).
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For the 12 women with redetection of C. trachomatis, typing
was attempted using the omp1 typing system described by
Jurstrand et al.11
Statistical methods
The analyses for the current study were restricted to 954 partici-
pants who returned self-taken repeat postal specimens. We ana-
lysed the intervention and control groups combined as all
women with chlamydia infection at baseline were referred for
treatment either shortly after recruitment (intervention group)
or after 12 months (deferred screening control group), and
repeat postal samples were provided later, a median of
16 months after recruitment (except in one case where the
sample was returned after only 11 months). As recommended at
recruitment, 25% (235/952) of participants got themselves
tested for chlamydia independent of the trial during follow-up,
and this was equally distributed between the intervention (123/
499) and control groups (112/453). We investigated the preva-
lence of chlamydia at baseline, and the rate of incident and
redetected infections at follow-up. Infection in both baseline
and follow-up samples was classiﬁed as redetection, recognising
that these cases may either be due to clearance (including clear-
ance following treatment) and subsequent reinfection, or persist-
ent infection. However, the majority of redetected cases are
likely to be reinfections, since all women with chlamydia at
baseline were ultimately referred for treatment,8 and around
half of any untreated infections would be expected to resolve
spontaneously within the year.12
We conducted exploratory analyses investigating demographic
and behavioural risk factors for incident and redetected chla-
mydia infections, and estimated relative risks (RRs) using bino-
mial regression (StataCorp 2011, Stata Statistical Software:
Release 12. College Station, Texas, USA: StataCorp LP).
Analyses of predictors for incident infection were adjusted for
age, as young age is a known risk factor for chlamydia. Due to
the small number of redetected infections, we only examined
the ﬁve risk factors which were shown to be independently asso-
ciated with incident infection.
We used the dates of the baseline and repeat samples as the
beginning and end dates of follow-up. Annual incidence rates
were estimated by dividing the number of observed new cases
by the total person-years followed up, for subjects negative at
baseline. Annual redetection rates were estimated by dividing
the number of redetected cases by the total person-years fol-
lowed up, for subjects positive at baseline. We then expressed
these as rates per 100 person-years. Calculation of the true inci-
dence or redetection rates would have required information on
the date of infection which was not available.
RESULTS
Participant characteristics
The mean age of the 954 participants who returned repeat
samples was 21.5 years (SD 2.9, range 16–27 years) and 26%
(251) were of an ethnic minority background (black African
n=94, black Caribbean n=74, black other n=12 and other
ethnic groups n=71). In all, 77% (737/954) were recruited
from universities and the remainder from FE colleges; 37%
(352/954) were teenagers aged <20 years.
Table 1 shows that women who returned repeat postal speci-
mens were similar to those who did not in the proportion who
reported a new partner in the previous year and who were aged
<16 years at ﬁrst sex. However, they were slightly older, and
less likely to be of black ethnicity or to have had chlamydia or
bacterial vaginosis at baseline.
Incidence of chlamydia infection
Among 907 women who were negative for chlamydia at base-
line and followed up for 11–32 (median 16) months, the pro-
portion with incident chlamydia infection was 4.6% (n=42,
95% CI 3.4% to 6.2%) (ﬁgure 1). Taking into account the total
follow-up time (1234 person-years), the estimated annual inci-
dence of infection was 3.4 per 100 person-years (95% CI 2.5 to
4.6 per 100 person-years). In participants aged <20 years, the
proportion with incident infection was 8.9% (29/326, 95% CI
6.0% to 12.5%) and the annual rate was 6.6 per 100 person-
years (95% CI 4.5 to 9.3 per 100 person-years). Predictors of
incident chlamydia infection were age <20 years (RR 4.0, 95%
CI 2.1 to 7.5), and (after adjusting for age) a new sexual partner
during 12 months follow-up (RR 4.4, 95% CI 2.0 to 9.9),
smoking (RR 2.2, 95% CI 1.2 to 3.9), baseline bacterial vagin-
osis (RR 2.0, 95% CI 1.1 to 3.9) and baseline high risk carcino-
genic human papillomavirus (RR 2.2, 95% CI 1.1 to 4.3)
(table 2).
Redetection rates of chlamydia infection
Among the 954 women providing follow-up samples, 4.9%
(n=47, 95% CI 3.6% to 6.5%) tested positive for chlamydia at
recruitment and 5.7% (n=54, 95% CI 4.3% to 7.3%) were
positive at follow-up. The proportion with redetected chlamydia
among 47 women positive at recruitment was 25.5% (n=12,
95% CI 13.9% to 40.3%). Taking into account the total
follow-up time of 65 person-years, the annual redetection rate
was 18.5 per 100 person-years (95% CI 9.9 to 30.0 per 100
person-years). Chlamydia redetection was not signiﬁcantly asso-
ciated with any of the tested risk factors, but numbers were
small (table 3).
Among the 12 women with redetection of chlamydia infec-
tion, six had baseline and follow-up specimens with adequate
DNA load for genetic typing. Four had the same omp1 geno-
type detected in both specimens suggesting treatment failure,
reinfection from an untreated partner or reinfection from a new
partner carrying the same genotype. Two, however, were
Table 1 Baseline characteristics of 2519* female students who
did (n=954) or did not (n=1565) provide repeat postal samples a
median of 16 months after recruitment
Characteristics
at baseline
% (n/N) of 1565
women who did not
return follow-up
samples
% (n/N) of 954
women who
returned follow-up
samples
Age <20 years 49.1 (769/1565) 36.9 (352/954)
Black ethnicity 32.6 (505/1550) 18.9 (180/952)
Smoker 34.5 (536/1556) 26.9 (256/952)
New partner in the
previous year
48.8 (509/1044) 48.8 (465/953)
Age <16 at first sex 29.7 (453/1525) 29.3 (277/945)
Oral contraception 43.7 (673/1541) 54.5 (518/951)
Uses condoms 58.3 (900/1542) 47.5 (452/951)
Chlamydia trachomatis 6.1 (96/1565) 4.9 (47/954)
Previous history of
C. trachomatis
5.4 (81/1492) 7.5 (68/908)
Mycoplasma genitalium 3.5 (51/1470) 2.9 (26/907)
Bacterial vaginosis 27.8 (333/1463) 17.1 (156/914)
Neisseria gonorrhoeae 0.5 (7/1483) 0.2 (2/914)
*Ten of the total 2529 women did not provide adequate samples for chlamydia
testing at baseline.
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probably infected from a new partner, as the genotype of the C.
trachomatis strain had changed between the two time points.
DISCUSSION
Principal ﬁndings
In this community based cohort, the annual incidence of chla-
mydia infection was 3.4 per 100 person-years. Predictors of
incident chlamydia infection were age <20 years, a new partner
in the previous year, smoking, and concurrent bacterial vaginosis
or high risk human papillomavirus. One in four women with
chlamydia at baseline tested positive again after a median of
16 months. Taking into account the total follow-up time, the
estimated annual redetection rate was 18.5 per 100
person-years.
Strengths and weaknesses
This is the ﬁrst study to examine incident and redetected chla-
mydia rates in a community sample of sexually active female stu-
dents. It provides much needed data on the rates of new
infections and the characteristics of those most affected. It
includes a large number of participants from ethnic minority
backgrounds and teenagers, who are often hard to reach. It was
a pragmatic study, where women diagnosed with an infection
were able to choose where and when to be treated. It involved
the use of self-taken vaginal samples, which are used in the
English NCSP and have a higher sensitivity for the detection of
chlamydia than urine samples.13 A higher follow-up rate was
achieved than reported for some other home sampling
studies.14 15 In addition, we had data on smoking, age at ﬁrst
sexual intercourse and rates of co-infections with other STIs.
M. genitalium may be a surrogate marker for a high number of
sexual partners.9 Although numbers were small, genetic typing
suggested that 2/6 redetected chlamydia infections were due to
a new sexual partner which is in line with previous reports.16 17
A limitation is that incidence rates are likely to have been
underestimated. First, women may have acquired and cleared an
infection in the time between baseline and follow-up. The
average duration of untreated chlamydia infection is unknown;
data suggest that most infections remain for over 60 days and
some may persist for years.12 18 Second, one in four women
reported that they had had an independent test for chlamydia
outside of the study during the follow-up period and may have
had an infection diagnosed and treated. Third, only 38% of the
cohort provided samples at follow-up, and these women were
slightly older, less likely to be of black ethnicity and had lower
rates of STIs at baseline, indicating that these were lower risk
women compared with non-responders.
Combining intervention and control groups might have intro-
duced bias. The rate of provision of follow-up samples by base-
line chlamydia positives was 25% (17/68) for intervention and
40% (30/75) for control women. The redetection rates also
varied by trial arm: 18% (3/17) for intervention and 30%
(9/30) for control women. A higher response among chlamydia
positives in the deferred screening group may have been due to
recent notiﬁcation of their positive baseline result, and some of
this group may have used the repeat swab to check their current
status before going for testing which might explain the higher
redetection rate. Despite this, these groups may be reasonably
Figure 1 Flowchart for 954 women
who provided repeat postal samples
11–32 (median 16) months after
recruitment.
Table 2 Predictors of incident chlamydia infection (n=42) in 907 women who were chlamydia negative at baseline and provided repeat postal
samples after 11–32 months
Percentage of women
with characteristic
Incidence of chlamydia %
(proportion) of women
Relative risk
(95% CI)
Adjusted relative
risk* (95% CI)Characteristic With characteristic Without characteristic
Age <20 years 35.9 8.9 (29/326) 2.2 (13/581) 4.0 (2.1 to 7.5) –
Black ethnicity 17.5 5.7 (9/158) 4.4 (33/747) 1.3 (0.6 to 2.6) 1.1 (0.5 to 2.2)
Smoker 27.1 7.8 (19/245) 3.5 (23/660) 2.2 (1.2 to 4.0) 2.2 (1.2 to 3.9)
New partner during 12 months follow-up 48.0 8.0 (35/435) 1.5 (7/471) 5.4 (2.4 to 12.0) 4.4 (2.0 to 9.9)
Condom use during 12 months follow-up† 55.0 5.5 (27/487) 3.8 (15/399) 1.5 (0.8 to 2.7) 1.2 (0.6 to 2.1)
Age at first sex <16 years 29.3 6.8 (18/263) 3.8 (24/636) 1.8 (1.0 to 3.3) 1.5 (0.8 to 2.7)
Neisseria gonorrhoeae‡ 0.2 0 (0/2) 4.7 (41/867) – –
Bacterial vaginosis‡ 16.2 8.5 (12/141) 3.7 (27/727) 2.3 (1.2 to 4.4) 2.0 (1.1 to 3.9)
Mycoplasma genitalium‡ 2.9 12.0 (3/25) 4.3 (36/837) 2.8 (0.9 to 8.5) 2.8 (2.3 to 9.0)
Carcinogenic HPV‡ 16.4 8.5 (11/130) 3.8 (25/663) 2.2 (1.1 to 4.5) 2.2 (1.1 to 4.3)
*Adjusted for age <20 years.
†No data available on consistency of use.
‡At baseline.
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similar as they were randomised from the same population, and
received the same advice about attending for testing and
treatment.
We had no data on possible treatment failure. We were also
unable to genotype six of the 12 paired samples as four carried
a C. trachomatis DNA load that was too low to allow genotyp-
ing, and two sets had one of the specimens used up for other
studies. Thus, we had insufﬁcient data to provide estimates of
the proportion of women with redetected infection who had
persistent infection versus reinfection. If the redetections were
mainly reinfections, then the redetection rate of 18.5 per 100
person-years should be considered an underestimate, as we used
the full follow-up time to return of the second swab in the cal-
culation of this rate, but reinfection would have occurred earlier
than this. The number of redetected infections was small, which
limited the investigation of potential risk factors. Finally, as
with all studies with a convenience sampling design, the general-
isability of the results is limited. Participants may not be repre-
sentative, and taking part in the trial and being educated about
chlamydia may have inﬂuenced their behaviour.
Comparison with other studies
Three other UK studies have examined incident and redetection
rates of chlamydia among under 25 year olds eligible for the
NCSP. Rates of retesting were lower than in our study and
nearly all participants were attending healthcare settings.4–6
Lamontagne et al found chlamydia incidence rates in women
varied between 4.6 and 10.6 per 100 person-years depending
on whether participants were recruited from a general practice
(GP) or a genitourinary medicine (GUM) clinic.5 As in our
study, incidence rates were also highest among the younger age
groups and those reporting new sexual partners. Redetection
rates ranged from 21.1 to 29.9 per 100 person-years in GUM
and GP settings, respectively.
Although population and register based studies in slightly
older women found lower redetection rates,19 20 a recent
primary care based cohort of Australian women aged ≤25 years
found incidence and redetection rates of 4.4% and 22.3%17
which are similar to the ﬁndings of ours and others.4 6 21 Few
studies had data on smoking and co-infections.
Implications
These data suggest that the annual incidence and redetection
rates of chlamydia infection in women in the community are
high, particularly among sexually active teenagers. They high-
light the need for targeted screening among those with a new
partner or recent history of infection. The recent change to the
guidelines22 supporting routine retesting of positives needs to be
publicised. A modelling study by Heijne et al23 suggests a
window of 2–5 months, which is in line with retesting policies
in other countries.24–26
Key messages
▸ The annual incidence of chlamydia in sexually active female
students was 3.4 per 100 person-years, but 6.6 per 100
person-years in teenagers.
▸ Incident chlamydia infection was independently associated
with a new sexual partner, smoking, bacterial vaginosis,
high risk human papillomavirus and age <20 years.
▸ One in four women with chlamydia at baseline tested
positive again after a median of 16 months.
▸ Recommendations from chlamydia screening programmes to
routinely retest those who have been recently treated for
chlamydia should be publicised.
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